• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Feb. 20, 2019

View Archived Issues

Skeptics Intercept victory pass in NASH; win leaving others in field wide open?

After excitement on Wall Street early in the day about pivotal phase III data with obeticholic acid (OCA) in patients with liver fibrosis due to nonalcoholic steatohepatitis (NASH), shares of New York-based Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) settled to close at $117.57, up $6.75. Read More

Inventiva shares crumple after midstage miss for lead antifibrotic candidate

Inventiva SA, of Daix, France, said a phase IIb trial evaluating the company's lead candidate, lanifibranor, for the treatment of diffuse cutaneous systemic sclerosis failed to meet its primary endpoint, sending company shares (PARIS:IVA) down 49.5 percent to close at €4.13 (US$4.68) on Tuesday. Investigators found no statistically significant difference between the placebo and lanifibranor-treated groups for the primary outcome of mean absolute change from baseline in a multipoint measure of skin thickness. Read More

No pain, big gain? Tanezumab scores in phase III back pain trial

DUBLIN – Pfizer Inc.'s and Eli Lilly and Co.'s venerable antibody, tanezumab, a longtime clinical candidate for various pain indications, is lumbering toward the finish line. The two partners reported a second positive phase III readout inside a month. This time around, it's in patients with chronic lower back pain. The higher dose of the drug (10 mg) used in the study attained the primary endpoint of a statistically significant improvement in pain at 16 weeks, as compared with placebo. A lower dose (5 mg) did not attain statistical significance at the same time point. Read More

Researchers around the world to collaborate on new model for neuroscience research

WASHINGTON – Later this year, 21 principal investigators working in six countries will press the start button on an identical series of experiments in each of their labs and begin to generate data for the first brain-wide neural model of decision-making in mice. Read More

Machine learning adding to reproducibility crisis in biomedical research

WASHINGTON – The use of machine learning to analyze large datasets is throwing up more and more spurious signals and accelerating the reproducibility crisis in biomedical research. Read More

Australia's Bionomics revives BNC-210 in PTSD following analysis of phase II failure

PERTH, Australia – Adelaide-based Bionomics Inc. is reviving lead compound BNC-210 after a deeper analysis of phase II data showed a positive effect in post-traumatic stress disorder (PTSD). Read More

Class action on insulin prices fails RICO test, but state claims advance

Although the rebate system used to set list prices for insulin products in the U.S. bears all the hallmarks needed for a Racketeer Influenced and Corrupt Organizations (RICO) action, a federal judge ruled that patients lack the standing, at least in the Third Circuit, to bring such actions against drug companies because they don't buy the drugs directly from the manufacturer. Read More

Financings

Ico Therapeutics Inc., of Vancouver, British Columbia, said it upsized its nonbrokered private placement to CA$1.25 million (US$942,695). Each unit issued consists of one common share and one common share purchase warrant exercisable at $0.075 for 36 months from the date of the closing. The private placement is expected to occur in several closings. Read More

Earnings

Spark Therapeutics Inc., of Philadelphia, said for the year ended Dec. 31, it recognized $64.7 million in total revenue, of which $27 million was due to net product sales of Luxturna (voretigene neparvovec-rzyl), its gene therapy for treating retinal dystrophy arising from biallelic RPE65 mutations, and $37.8 million as earned in contract revenue. Read More

Other news to note

Saniona AB, of Copenhagen, completed preclinical development for SAN-711, a selective GABA-A alpha3 modulator for itching and neuropathic pain. The company plans to start a phase I study in summer 2019. Read More

Regulatory front

After first saying no, the U.K.'s National Institute for Health and Care Excellence (NICE) published draft guidance recommending Perjeta (pertuzumab, Roche Holding AG) for treating people who have had surgery for early HER2-positive breast cancer and whose cancer has already spread to their lymph nodes.  Read More

Clinical data for Feb. 19, 2019

Read More

Regulatory actions for Feb. 19, 2019

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 4, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 4, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • KT-621: a first-in-class STAT6 degrader for Th2-driven diseases

    BioWorld Science
    STAT6 plays a central role in regulating Th2-driven immune responses. Recent studies have identified gain-of-function mutations in the STAT6 gene that are...
  • Woman holding neck

    Merus combo trounces Keytruda in head-and-neck phase II

    BioWorld
    Investor hopes rose sharply for Merus NV’s phase III trials – data should roll out next year – with bispecific antibody petosemtamab after mid-stage results...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe